Menu Search
Equities

MDxHealth SA

MDXH:NAQ

MDxHealth SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.63
  • Today's Change0.06 / 2.33%
  • Shares traded10.19k
  • 1 Year change-4.36%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year MDxHealth SA grew revenues 89.43% from 37.05m to 70.19m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -44.04m to -43.10m.
Gross margin62.64%
Net profit margin-50.54%
Operating margin-30.83%
Return on assets-29.85%
Return on equity-457.29%
Return on investment-43.63%
More ▼

Cash flow in USDView more

In 2023, MDxHealth SA increased its cash reserves by 44.36%, or 6.88m. Cash Flow from Financing totalled 32.28m or 45.99% of revenues. In addition the company used 21.50m for operations while cash used for investing totalled 3.93m.
Cash flow per share-1.41
Price/Cash flow per share--
Book value per share-0.3229
Tangible book value per share-3.22
More ▼

Balance sheet in USDView more

MDxHealth SA has a Debt to Total Capital ratio of 118.42%, a lower figure than the previous year's 144.88%.
Current ratio0.9086
Quick ratio0.8252
Total debt/total equity--
Total debt/total capital1.18
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.